Byung Ju Kang1, Sang-Do Lee2, Yeon-Mok Oh1, Jae Seung Lee3. 1. Department of Pulmonary and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea. 2. Department of Pulmonary and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea; Center for Pulmonary Hypertension and Venous Thromboembolism, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea. 3. Department of Pulmonary and Critical Care Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea; Center for Pulmonary Hypertension and Venous Thromboembolism, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea. Electronic address: jsdoc1186@daum.net.
Abstract
OBJECTIVES: We compared the survival of patients with idiopathic pulmonary arterial hypertension (IPAH), receiving conventional and targeted therapies. BACKGROUND: IPAH is an incurable disease with high mortality. To manage IPAH, several targeted therapies have been used in Korea. METHODS: We performed a retrospective study of 71 patients diagnosed with IPAH in a tertiary hospital between January 1994 and February 2013. Patients were classified into "conventional therapy group" (treated with conventional therapies and/or beraprost) and "targeted therapy group" (treated with targeted therapies other than beraprost). RESULTS: The median age of the patients was 33 years and 50 patients were female. The survival rate at 1, 3, 5, and 10 years was 80.1% 62.0%, 51.5%, and 26.8%, respectively. The survival rate in the targeted therapy group was greater than in the conventional therapy group (p-value = 0.026). CONCLUSIONS: We believe targeted therapies would improve survival benefits in IPAH patients.
OBJECTIVES: We compared the survival of patients with idiopathic pulmonary arterial hypertension (IPAH), receiving conventional and targeted therapies. BACKGROUND: IPAH is an incurable disease with high mortality. To manage IPAH, several targeted therapies have been used in Korea. METHODS: We performed a retrospective study of 71 patients diagnosed with IPAH in a tertiary hospital between January 1994 and February 2013. Patients were classified into "conventional therapy group" (treated with conventional therapies and/or beraprost) and "targeted therapy group" (treated with targeted therapies other than beraprost). RESULTS: The median age of the patients was 33 years and 50 patients were female. The survival rate at 1, 3, 5, and 10 years was 80.1% 62.0%, 51.5%, and 26.8%, respectively. The survival rate in the targeted therapy group was greater than in the conventional therapy group (p-value = 0.026). CONCLUSIONS: We believe targeted therapies would improve survival benefits in IPAH patients.
Authors: Soo Han Kim; Jae Won Lee; Jung-Min Ahn; Dae-Hee Kim; Jong-Min Song; Sang-Do Lee; Jae Seung Lee Journal: Korean J Intern Med Date: 2016-10-13 Impact factor: 2.884